Gordon J, et al. - Utilizing data from the DEPICT (Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes) clinical trial programme, researchers explored the connections between hypoglycaemia, BMI and quality of life, and analyzed the effect of dapagliflozin on patient-reported treatment satisfaction in patients with T1DM. Findings suggested an association of increases in hypoglycaemia and BMI with reduced quality of life in people with T1DM. Patients treated with dapagliflozin achieved a decline in HbA1c whilst avoiding a rise in hypoglycaemic events. Treatment with dapagliflozin was also linked to an improvement in treatment satisfaction.